These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554 [TBL] [Abstract][Full Text] [Related]
3. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130 [TBL] [Abstract][Full Text] [Related]
4. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276 [TBL] [Abstract][Full Text] [Related]
5. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor. Kim RS; Yaghy A; Wilde LR; Shields CL JAMA Ophthalmol; 2020 Apr; 138(4):418-419. PubMed ID: 32163103 [No Abstract] [Full Text] [Related]
6. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Gorcea CM; Burthem J; Tholouli E Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296 [TBL] [Abstract][Full Text] [Related]
7. Gilteritinib or Chemotherapy for Relapsed or Refractory Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578 [TBL] [Abstract][Full Text] [Related]
8. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841 [TBL] [Abstract][Full Text] [Related]
9. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia. Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232 [TBL] [Abstract][Full Text] [Related]
12. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. Zeidan AM; Qi CZ; Yang H; Garnham A; Shah MV; Pandya BJ Leuk Lymphoma; 2022 Mar; 63(3):762-764. PubMed ID: 34749571 [No Abstract] [Full Text] [Related]
13. Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation. Akahane D; Moriyama M; Yoshizawa S; Katagiri S; Fujimoto H; Gotoh A Geriatr Gerontol Int; 2019 Oct; 19(10):1063-1064. PubMed ID: 31602758 [No Abstract] [Full Text] [Related]
14. Gilteritinib induces differentiation in relapsed and refractory McMahon CM; Canaani J; Rea B; Sargent RL; Qualtieri JN; Watt CD; Morrissette JJD; Carroll M; Perl AE Blood Adv; 2019 May; 3(10):1581-1585. PubMed ID: 31122910 [TBL] [Abstract][Full Text] [Related]
15. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Weis TM; Marini BL; Bixby DL; Perissinotti AJ Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288 [TBL] [Abstract][Full Text] [Related]
16. Closing in on targeted therapy for acute myeloid leukaemia. The Lancet Haematology Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709 [No Abstract] [Full Text] [Related]
18. First new drug approval for AML in 15 years. Sheridan C Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411 [No Abstract] [Full Text] [Related]
19. Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. Blood Adv; 2022 Nov; 6(22):5886. PubMed ID: 36378495 [No Abstract] [Full Text] [Related]
20. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]